Literature DB >> 14715277

siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme.

Takanori Yokota1, Makoto Miyagishi, Taro Hino, Ryusuke Matsumura, Andrea Tasinato, Makoto Urushitani, Rammohan V Rao, Ryosuke Takahashi, Dale E Bredesen, Kazunari Taira, Hidehiro Mizusawa, Tasinato Andrea.   

Abstract

In many of autosomal dominant diseases such as familial amyotrophic lateral sclerosis (ALS) with SOD1 mutation, a missense point mutation may induce the disease by its gain of adverse property. Reduction of such a mutant protein expression is expected to improve the disease phenotype. Duplex of 21-nt RNA, known as siRNA, has recently emerged as a powerful tool to silence gene, but the sequence specificity and efficacies have not been fully studied in comparison with ribozyme and DNA enzyme. We could make the siRNA which recognized even a single nucleotide alternation and selectively suppress G93A SOD1 expression leaving wild-type SOD1 intact. In mammalian cells, the siRNA much more efficiently suppressed the expression of mutant SOD1 than ribozyme or DNA enzyme. Furthermore, these siRNAs could suppress cell death of Neuro2a induced by over-expression of mutant SOD1s with stress of proteasome inhibition. Our results support the feasibility of utilizing siRNA-based gene therapy of familial ALS with mutant SOD1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715277     DOI: 10.1016/j.bbrc.2003.12.098

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

2.  Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery.

Authors:  M Gorbatyuk; V Justilien; J Liu; W W Hauswirth; A S Lewin
Journal:  Vision Res       Date:  2007-02-12       Impact factor: 1.886

3.  Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury.

Authors:  Takashi Hirai; Mitsuhiro Enomoto; Hidetoshi Kaburagi; Shinichi Sotome; Kie Yoshida-Tanaka; Madoka Ukegawa; Hiroya Kuwahara; Mariko Yamamoto; Mio Tajiri; Haruka Miyata; Yukihiko Hirai; Makoto Tominaga; Kenichi Shinomiya; Hidehiro Mizusawa; Atsushi Okawa; Takanori Yokota
Journal:  Mol Ther       Date:  2013-10-28       Impact factor: 11.454

Review 4.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

5.  Specific Silencing of L392V PSEN1 Mutant Allele by RNA Interference.

Authors:  Malgorzata Sierant; Alina Paduszynska; Julia Kazmierczak-Baranska; Benedetta Nacmias; Sandro Sorbi; Silvia Bagnoli; Elzbieta Sochacka; Barbara Nawrot
Journal:  Int J Alzheimers Dis       Date:  2011-04-07

6.  Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy.

Authors:  Haihui Liao; Alan D Irvine; Caroline J Macewen; Kathryn H Weed; Louise Porter; Laura D Corden; A Bethany Gibson; Jonathan E Moore; Frances J D Smith; W H Irwin McLean; C B Tara Moore
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

Review 7.  RNA Dysregulation in Amyotrophic Lateral Sclerosis.

Authors:  Zoe Butti; Shunmoogum A Patten
Journal:  Front Genet       Date:  2019-01-22       Impact factor: 4.599

Review 8.  RNA interference: from gene silencing to gene-specific therapeutics.

Authors:  Ray K M Leung; Paul A Whittaker
Journal:  Pharmacol Ther       Date:  2005-08       Impact factor: 12.310

9.  Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro.

Authors:  Anxun Wang; Bin Zhang; Hongzhang Huang; Leitao Zhang; Donglin Zeng; Qian Tao; Jianguang Wang; Chaobin Pan
Journal:  BMC Cancer       Date:  2008-06-30       Impact factor: 4.430

10.  Intraperitoneal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice.

Authors:  Akira Machida; Hiroya Kuwahara; Azat Mayra; Takayuki Kubodera; Takashi Hirai; Fumiko Sunaga; Mio Tajiri; Yukihiko Hirai; Takashi Shimada; Hidehiro Mizusawa; Takanori Yokota
Journal:  Mol Pain       Date:  2013-07-18       Impact factor: 3.395

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.